InMed Pharmaceuticals Inc.
INM
$0.88
-$0.01-1.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.73% | -3.27% | 7.50% | -12.53% | -11.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.73% | -3.27% | 7.50% | -12.53% | -11.94% |
| Cost of Revenue | 1.44% | -6.07% | -7.46% | -2.79% | -7.60% |
| Gross Profit | -21.65% | 2.75% | 55.02% | -27.63% | -18.89% |
| SG&A Expenses | 6.11% | 14.03% | 17.18% | 15.72% | 15.73% |
| Depreciation & Amortization | -2.71% | -3.60% | -3.05% | -1.56% | 1.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.98% | 4.10% | 1.01% | 6.02% | 0.93% |
| Operating Income | -0.98% | -9.13% | 2.66% | -21.73% | -11.02% |
| Income Before Tax | 3.06% | -20.58% | -6.44% | -36.71% | -24.55% |
| Income Tax Expenses | -- | -- | -- | 294.44% | 115.15% |
| Earnings from Continuing Operations | 3.15% | -20.46% | -6.34% | -36.79% | -24.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.15% | -20.46% | -6.34% | -36.79% | -24.60% |
| EBIT | -0.98% | -9.13% | 2.66% | -21.73% | -11.02% |
| EBITDA | -1.09% | -9.53% | 2.65% | -22.52% | -11.33% |
| EPS Basic | 69.27% | 48.60% | 64.31% | 49.85% | 57.65% |
| Normalized Basic EPS | 69.24% | 48.54% | 64.29% | 49.89% | 57.67% |
| EPS Diluted | 69.27% | 48.60% | 64.31% | 49.85% | 57.65% |
| Normalized Diluted EPS | 69.24% | 48.54% | 64.29% | 49.89% | 57.67% |
| Average Basic Shares Outstanding | 308.68% | 266.25% | 156.61% | 139.48% | 154.74% |
| Average Diluted Shares Outstanding | 308.68% | 266.25% | 156.61% | 139.48% | 154.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |